Vyome Holdings (HIND) Operating Expenses (2015 - 2026)
Vyome Holdings (HIND) posted quarterly Operating Expenses of $1.1 million for Q1 2026, up 224.43% year-over-year from $353417.0 in Q1 2025, and down 16.74% quarter-over-quarter from $1.4 million in Q4 2025.
Vyome Holdings (HIND) Operating Expenses (2015 - 2026) Analysis & Trends
Vyome Holdings' Operating Expenses history runs 12 years deep, the most recent figure standing at $1.1 million for Q1 2026.
- In Q1 2026, Operating Expenses rose 224.43% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $14.5 million (up 246.49% YoY), while the FY2025 annual figure was $10.7 million, up 788.31% from the prior year.
- Operating Expenses for Q1 2026 stood at $1.1 million, down from $1.4 million in the prior quarter.
- The five-year high for Operating Expenses was $18.3 million in Q4 2022, with the low at $318063.0 in Q3 2024.
- The 5-year median for Operating Expenses is $3.7 million (2023), against an average of $5.7 million.
- The sharpest annual moves came in 2024 and 2025: Operating Expenses tumbled 93.85% in 2024, then soared 2601.46% in 2025.
- Vyome Holdings' Operating Expenses stood at $18.3 million in 2022, then tumbled by 79.57% to $3.7 million in 2023, then tumbled by 91.47% to $318767.0 in 2024, then jumped by 332.02% to $1.4 million in 2025, then slipped by 16.74% to $1.1 million in 2026.
- Business Quant data shows HIND's Operating Expenses at $1.1 million in Q1 2026, $1.4 million in Q4 2025, and $8.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Vyome Holdings | 16.00 Mn | 8.11 Mn | 11,658.00 | 874,224.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 874,224.00 |
| Mar 31, 2026 | 1.15 Mn |
| Dec 31, 2025 | 1.38 Mn |
| Sep 30, 2025 | 8.59 Mn |
| Jun 30, 2025 | 3.36 Mn |
| Mar 31, 2025 | 353,417.00 |
| Dec 31, 2024 | 318,767.00 |
| Sep 30, 2024 | 318,063.00 |
| Jun 30, 2024 | 3.19 Mn |
| Mar 31, 2024 | 3.38 Mn |
| Dec 31, 2023 | 3.74 Mn |
| Sep 30, 2023 | 5.17 Mn |
| Jun 30, 2023 | 5.17 Mn |
| Mar 31, 2023 | 6.86 Mn |
| Dec 31, 2022 | 18.29 Mn |
| Sep 30, 2022 | 14.40 Mn |
| Jun 30, 2022 | 11.13 Mn |
| Mar 31, 2022 | 9.33 Mn |
| Dec 31, 2021 | 39.29 Mn |
| Sep 30, 2021 | 16.55 Mn |